Gastroesophageal Reflux Disease Market Predicted To See Upsurge Through 2034, Highlights Delveinsight
Gastroesophageal Reflux disease market Insights. DelveInsight's Gastroesophageal Reflux Disease Market report offers an in-depth understanding of the epide ...
Phathom spikes as Cantor Fitzgerald bullish on IP claims
Phathom Pharmaceuticals (PHAT) stock rises as Cantor Fitzgerald issues an Overweight rating, rejecting its IP-rights related risk. Read more here.
Phathom Pharmaceuticals initiated at Cantor Fitzgerald on ‘significant’ upside
Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target The firm cited ...
Phathom Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target Maximize Your Portfolio ...
ETF Daily News14d
Q1 EPS Estimates for Allegiant Travel Cut by Seaport Res Ptn
Allegiant Travel (NASDAQ:ALGT – Free Report) – Seaport Res Ptn dropped their Q1 2025 earnings estimates for shares of Allegiant Travel in a report released on Wednesday, February 5th.
Yahoo Finance14d
Phathom Pharmaceuticals, Inc. (PHAT)
Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...
Stifel maintains $28 target on Phathom Pharmaceuticals stock
Stifel analysts have maintained a Buy rating and a $28.00 price target for Phathom Pharmaceuticals (NASDAQ:PHAT), focusing on the company's recent developments. Currently trading at $5.59, ...